#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hypereosinophilic syndrome Mucopolysaccharidosis III Primary hyperoxaluria Ewing's sarcoma Philadelphia positive chronic myeloid leukaemia Dementia Alzheimer's type Round cell liposarcoma Carcinoid tumour Lymphatic malformation Glycogen storage disease type II Cholangiosarcoma Albright's disease Alpha-1 antitrypsin deficiency Hypotransferrinaemia Pleomorphic leiomyosarcoma More trials…

    Learn about Rare Diseases

    Rosai-Dorfman syndrome – Treatment Chordoma – Trials in Disease Hairy cell leukaemia recurrent – Basic Information IgA nephropathy – Trials in Disease Waldenstrom’s macroglobulinaemia refractory – Life with Disease Nephroblastoma – Diagnostics Prolymphocytic leukaemia – Basic Information Osteosarcoma – Treatment Hyperoxaluria Synovial sarcoma recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ciltacabtagene Autoleucel Blu-451 Cd19-Car_Lenti_Allo Sacituzumab Govitecan Gefurulimab Nivolumab Afamitresgene Autoleucel Clozapine Evencaleucel SODIUM IBANDRONATE Pegargiminase Garetosmab Azilsartan Medoxomil Insulin Icodec Remimazolam Vericiguat Aluminium Oxide Ginisortamab Ima203Cd8 Prednisolone More therapies…

    Learn about Your Condition

    Heart transplant Delayed graft function Hip fracture Neck pain Cluster headache Retinopathy proliferative Pulmonary embolism Migraine with aura Leiomyosarcoma recurrent B-cell lymphoma Rubella Rett syndrome Oesophageal adenocarcinoma Schizoaffective disorder Pancreatic failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatitis atopic

  • Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Sodium Chloride
    Bulgaria Czechia Germany Hungary Poland Spain

  • Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

    Recruiting

    3 1
    Investigated Diseases:
    • Eczema
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Czechia France Germany Poland Spain

  • A Study of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis Who Did Not Respond Well Enough to Dupilumab Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Upadacitinib
    • Dupilumab
    Italy Romania Spain

  • Testing two moisturizing creams with urea, propylene glycol, and propylene glycol alone for preventing flare-ups in patients with atopic dermatitis

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Urea
    • Propylene Glycol
    Norway Sweden

  • Study of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness

    Recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Abrocitinib
    Germany Hungary Poland Spain

  • Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

    Recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Apg777
    Czechia France Germany Hungary Poland Spain
1 2 3 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!